Gemtuzumab ozogamicin: is there room for salvage?
WT Clarke, PW Marks - Blood, The Journal of the American …, 2010 - ashpublications.org
On May 17, 2000, gemtuzumab ozogamicin received marketing approval from the US Food
and Drug Administration (FDA) under accelerated approval regulations for the treatment of …
and Drug Administration (FDA) under accelerated approval regulations for the treatment of …
[HTML][HTML] Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 …
Arecent source data meta-analysis of randomized trials in adults assessing the
immunoconjugate gemtuzumab ozogamicin combined with standard chemotherapy in acute …
immunoconjugate gemtuzumab ozogamicin combined with standard chemotherapy in acute …
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia
GJ Roboz, MA Knovich, RL Bayer… - Leukemia & …, 2002 - Taylor & Francis
The objective of this work was to determine the safety and efficacy of gemtuzumab
ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the …
ozogamicin in patients with poor prognosis acute myeloid leukemia (AML). Patients with the …
Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo
J Golay, N Di Gaetano, D Amico… - British journal of …, 2005 - Wiley Online Library
Gemtuzumab ozogamicin (GO) is a humanized anti‐CD33 antibody conjugated with the
cytotoxic drug calicheamicin and approved for the treatment of relapsed acute myeloid …
cytotoxic drug calicheamicin and approved for the treatment of relapsed acute myeloid …
Investigational CD33-targeted therapeutics for acute myeloid leukemia
RB Walter - Expert opinion on investigational drugs, 2018 - Taylor & Francis
Introduction: There is long-standing interest in drugs targeting the myeloid differentiation
antigen CD33 in acute myeloid leukemia (AML). Positive results from randomized trials with …
antigen CD33 in acute myeloid leukemia (AML). Positive results from randomized trials with …
The EMA review of mylotarg (gemtuzumab ozogamicin) for the treatment of acute myeloid leukemia
S Ali, HM Dunmore, D Karres, JL Hay… - The …, 2019 - academic.oup.com
Abstract On February 22, 2018, the Committee for Medicinal Products for Human Use
(CHMP) adopted a positive opinion, recommending the granting of a marketing …
(CHMP) adopted a positive opinion, recommending the granting of a marketing …
Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression
P Chevallier, B Mahe, R Garand, P Talmant… - International journal of …, 2008 - Springer
Gemtuzumab Ozogamicin (GO) is a humanized anti-CD33 antibody conjugated with a
cytotoxic antitumor antibiotic, calicheamicin-g1. It was developed at the end of the nineties …
cytotoxic antitumor antibiotic, calicheamicin-g1. It was developed at the end of the nineties …
Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3
D Amico, AM Barbui, E Erba, A Rambaldi, M Introna… - Blood, 2003 - ashpublications.org
Gemtuzumab ozogamicin (GO) is a humanized anti-CD33 antibody conjugated to the
anticancer agent calicheamicin, approved for the treatment of CD33+-relapsed acute …
anticancer agent calicheamicin, approved for the treatment of CD33+-relapsed acute …
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin–induced cytotoxicity
Abstract Gemtuzumab ozogamicin (GO; Mylotarg), a novel immunoconjugate used for
treatment of acute myeloid leukemia (AML), contains the humanized anti-CD33 antibody …
treatment of acute myeloid leukemia (AML), contains the humanized anti-CD33 antibody …
[HTML][HTML] The addition of gemtuzumab ozogamicin to induction chemotherapy in acute myeloid leukaemia: an individualpatient data meta-analysis of randomised trials …
RK Hills, S Castaigne, FR Appelbaum… - The Lancet …, 2014 - ncbi.nlm.nih.gov
Background Gemtuzumab Ozogamicin (GO) was the first example of antibody directed
chemotherapy in cancer and developed for Acute Myeloid Leukaemia. Its role has been …
chemotherapy in cancer and developed for Acute Myeloid Leukaemia. Its role has been …